References:
  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
  2. Abrams P, Cardozo L, Fall M, Griffiths D, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.Neurourol Urodynam 2002; 21: 167-178.
  3. Kupelian V, Wei JT, O’Leary MP, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med 2006; 166: 2381-2387.
  4. Calais Da Silva F, Marquis P, Deschaseaux P et al. Relative importance of sexuality and quality of life in patients with prostatic symptoms.Eur Urol 1997; 31: 272–280.
  5. Emberton M, Martorana G. BPH: social impact and patient’s perspective. Eur Urol Suppl. 2006; 5: 991–996.
  6. Hong SJ, Rayford W, Valiquette L, Emberton M. The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int 2005; 95: 15–19.
  7. Gravas S, Cornu JN, Gacci M, et al. Management of Non-neurogenic Male LUTS.https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts
  8. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012; 188 (6 Suppl): 2455–2463.
  9. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.JAMA 2006; 296: 2319–2328.
  10. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009; 182: 2825–2830.
  11. Matsuo T, Miyata Y, Kakoki K, et al. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. BMC Urol 2016; 16: 45.
  12. Gacci M, Sebastianelli A, Spatafora P, et al. Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. Ther Adv Urol 2017; 10: 79–92.
  13. Borkowski T, Golabek T, Chlosta PL, Borkowski A. Evaluation and management of male lower urinary tract symptoms: treatment patterns and guidelines in a correlation study among Polish urology consultants. Arch Med Sci 2015; 11: 1340–1351.
  14. Barry MJ, Fowler FJ Jr, O’Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549–1557.
  15. Prajsner A, Chudek J, Szybalska A, Piotrowicz K, Zejda J, Więcek A. ,Socioeconomic profile of elderly Polish men treated for benign prostate hyperplasia: Results of the population-based PolSenior study.Eur Geriatr Med 2015; 6: 53–57.
  16. Vouri SM, Strope SA, Olsen MA, Xian H, Schootman M. Antimuscarinic Use in Men Treated With Bladder Outlet Obstruction Medication Therapy.Urology 2018; 122: 76–82.
  17. Errando-Smet C, Müller-Arteaga C, Hernández M, Roset M. Diagnosis and treatment of male patients with lower urinary tract symptoms in Spain - The MERCURY Study. Do urologists follow the recommendations of the European guidelines? Actas Urol Esp 2018; 42: 323–330.
  18. Azzouni F, Mohler J. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment. Urology. 2012 ; 79: 1197–1205.
  19. Azzouni F, Mohler J. Role of 5α-reductase inhibitors in benign prostatic diseases. Prostate Cancer Prostatic Dis 2012; 15: 222–230.
  20. Barlik M, Jacyków D, Lewandowska B, Mirosław J, Siwiak K, Wągrowska U. Household budget survey in 2018. Statistics Poland.https://stat.gov.pl/obszary-tematyczne/warunki-zycia/dochody-wydatki-i-warunki-zycia-ludnosci/budzety-gospodarstw-domowych-w-2018-r-,9,13.html(published Sept 27 2019).
Table 1: The characteristics of the analysed group of men with prostatic enlargement, pharmacologically treated for BPH.